Repligen (NASDAQ:RGEN) PT Lowered to $200.00 at JPMorgan Chase & Co.

Repligen (NASDAQ:RGEN) had its price target lowered by JPMorgan Chase & Co. from $230.00 to $200.00 in a research note released on Thursday, Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.

Several other analysts have also weighed in on RGEN. Stifel Nicolaus increased their price target on Repligen from $165.00 to $207.00 and gave the company a buy rating in a report on Thursday, February 22nd. KeyCorp increased their target price on Repligen from $210.00 to $220.00 and gave the stock an overweight rating in a research note on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $197.75.

Repligen Trading Up 0.4 %

NASDAQ:RGEN traded up $0.74 during midday trading on Thursday, hitting $167.05. 454,984 shares of the company traded hands, compared to its average volume of 538,521. The firm’s fifty day moving average is $180.81 and its 200-day moving average is $174.09. Repligen has a 12-month low of $110.45 and a 12-month high of $211.13. The firm has a market capitalization of $9.33 billion, a P/E ratio of 668.23, a P/E/G ratio of 5.46 and a beta of 1.03. The company has a current ratio of 6.35, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. During the same quarter in the previous year, the company posted $0.64 EPS. The business’s quarterly revenue was down 17.1% on a year-over-year basis. On average, sell-side analysts predict that Repligen will post 1.46 EPS for the current year.

Insider Transactions at Repligen

In other news, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the sale, the director now owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,597 shares of company stock valued at $5,039,532. 1.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Repligen

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Repligen by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 5,078,294 shares of the biotechnology company’s stock valued at $913,077,000 after purchasing an additional 33,404 shares in the last quarter. Artisan Partners Limited Partnership raised its stake in shares of Repligen by 11.3% in the third quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company’s stock worth $247,558,000 after purchasing an additional 157,807 shares during the last quarter. Brown Capital Management LLC raised its stake in shares of Repligen by 5.8% in the fourth quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock worth $274,207,000 after purchasing an additional 83,416 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Repligen by 2.1% in the third quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company’s stock worth $222,075,000 after purchasing an additional 29,215 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Repligen by 13.0% in the third quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company’s stock worth $190,117,000 after purchasing an additional 137,220 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.